In early April, as covid-19 cases and deaths in New York City were rising to horrifying numbers, Tal Zaks, the chief medical officer of Moderna, a Cambridge-based biotech company, was concerned about time. In just three months, his company had created an experimental vaccine to inoculate against covid-19, and begun to inject the vaccine into humans, under the guidance of the National Institute of Allergy and Infectious Diseases, in a Phase I clinical trial involving forty-five healthy men and women.
